Servier marks 40 years in Brazil with plans for new meds and investment

Privately-held Servier has marked 40 years of operations in Brazil by announcing plans to launch 15 new medicines not only for diabetes, but also for cancer and cardiovascular diseases – the country’s second biggest killers.

The new drug launches to take place over the next five years are part of a series of investments in the South American country revealed by the French pharma company.

With a factory producing 500 million tablets per year, and a research and development center where more than 20 clinical trials have already been performed, the company is increasingly investing in research and supporting social projects alongside Brazilian medical societies and public research institutions.